Mesa Laboratories, Inc.
MLABTechnologyNASDAQScientific & Technical Instruments · Last scanned Jul 18, 2026
Scan Results
Daily timeframeMesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The company carries a $541.1M market cap, placing it firmly in the small-cap category. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Market Cap
$541.1M
Beta
0.93
P/E (TTM)
82.30
P/E (Fwd)
7.98
EPS (TTM)
$1.19
EPS (Fwd)
$12.27
ROE
3.9%
ROA
2.7%
Cash
$28.6M
Total Debt
$168.8M
Free CF
$31.9M
52W Change
39.8%
Annual Financials
Cash vs Debt
On the balance sheet, MLAB has $28.6M in cash with $168.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $31.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 3.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $219.1M to $249.1M.
Mesa Laboratories, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Mesa Laboratories, Inc.'s trajectory.